Sameh Hanna

Sameh Hanna

Auto-generated profile, based on publicly available information

Sameh Hanna

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
BKBrett King
Brett King
MSMaryanne M Senna
Maryanne M Senna
NMNatasha Mesinkovska
Natasha Mesinkovska
CLCharles Lynde
Charles Lynde
MZMatthew Zirwas
Matthew Zirwas
JCJames Cassella
James Cassella
Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant hair regrowth in AA. The Phase 3 THRIVE-AA1 randomized, double-blinded, placebo-controlled trial (NCT04518995) evaluated safety and efficacy of the oral JAK1/JAK2 inhibitor deuruxolitinib in adult patients with AA. Patients aged 18-65 years with ≥50% hair loss were randomized to deuruxolitinib 8 mg BID, deuruxolitinib 12 mg BID, or placebo for 24 weeks. The primary endpoint was percentage of patients achieving Severity of Alopecia Tool (SALT) score ≤20. A key secondary endpoint was percentage of satisfaction of hair patient-reported outcome (SPRO) responders. Significantly higher proportions of patients taking deuruxolitinib met the primary endpoint (8 mg 29.6%; 12 mg 41.5% versus placebo 0.8%). Both deuruxolitinib doses achieved significant improvements in all secondary endpoints versus placebo, including SPRO (8 mg 42.1%; 12 mg 53.0% versus placebo 4.7%). Most treatment-emergent adverse events were mild or moderate, consistent with other oral JAK inhibitors. Further studies are required to understand longer-term safety, efficacy, and impact of treatment cessation. Both doses of deuruxolitinib were effective for hair regrowth. Patient satisfaction aligned with hair growth.

3 September 2019 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
SHSam Hanna
Sam Hanna
CZCatherine Zip
Catherine Zip
NSNeil H. Shear
Neil H. Shear
The topical calcineurin inhibitors (TCIs), tacrolimus (Protopic) and pimecrolimus (Elidel), were approved in the early 2000s and were widely used as a nonsteroid treatment for atopic dermatitis (AD) in adult and pediatric populations. In 2005, the addition of a boxed warning was mandated for TCIs based on a potential risk of malignancy, and there was subsequently a substantial decline in their use. Since then, evidence has mounted to support the safety of this class of medications and suggests that the increased risk of malignancy remains theoretical. This review aims to dispel some of the common myths surrounding the safety of TCIs by evaluating the key evidence regarding their safety and tolerability in adult and pediatric populations. Four major themes are addressed in a practical question-and-answer format: the risk of harm associated with TCIs including common and serious adverse events; warnings and precautions for their use including the risk of systemic absorption, immunosuppression, and malignancy; the comparative safety of TCIs; and suggestions for counselling patients about the risk of harm with TCIs. Based on the available evidence, international professional dermatological organizations and regulatory authorities have concluded that the benefits of TCIs outweigh their potential risks when used in the appropriate patient populations for the recommended duration of time.

18 September 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
ITIrina Turchin
Irina Turchin
LALorne Albrecht
Lorne Albrecht
SHSameh Hanna
Sameh Hanna
DKDimitrios Kyritsis
Dimitrios Kyritsis
WLWei-Jing Loo
Wei-Jing Loo
MGMelinda Gooderham
Melinda Gooderham
Seborrheic dermatitis is a common chronic inflammatory skin condition that primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds. While the exact pathophysiology of seborrheic dermatitis is not fully understood, it is believed to involve a combination of microbial dysbiosis, immune imbalance, and skin barrier dysfunction. Effective management of seborrheic dermatitis includes treatments that reduce Malassezia yeast colonization, control inflammation, normalize skin barrier dysfunction, and regulate sebum production. Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis. Systemic therapies are reserved for severe or resistant seborrheic dermatitis cases. The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management. This review provides an overview of current, as well as emerging therapeutic options, and discusses the importance of personalized treatment strategies in managing seborrheic dermatitis. This is the third in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.

18 September 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
ITIrina Turchin
Irina Turchin
LALorne Albrecht
Lorne Albrecht
SHSameh Hanna
Sameh Hanna
DKDimitrios Kyritsis
Dimitrios Kyritsis
WLWei Jing Loo
Wei Jing Loo
MGMelinda Gooderham
Melinda Gooderham
Seborrheic dermatitis is a common chronic dermatosis predominantly affecting sebum-rich areas. The diagnosis of seborrheic dermatitis can be challenging due to its clinical resemblance to other dermatoses. Seborrheic dermatitis can significantly impact quality of life, particularly in those with pruritus and dyspigmentation involving the facial region. The pathogenesis of seborrheic dermatitis is complex, and while its etiology is not yet fully understood, current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction. This review provides an updated overview of seborrheic dermatitis epidemiology, burden of disease, and pathophysiology, highlighting the integral roles of microbiome, inflammation, and skin barrier dysfunction in its pathogenesis. This is the first in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.

18 September 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
ITIrina Turchin
Irina Turchin
LALorne Albrecht
Lorne Albrecht
SHSameh Hanna
Sameh Hanna
DKDimitrios Kyritsis
Dimitrios Kyritsis
WLWei Jing Loo
Wei Jing Loo
MGMelinda Gooderham
Melinda Gooderham
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face. Its presentation varies between children and adults, as well as across different skin tones. Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis. Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis. The pathophysiology of seborrheic dermatitis involves a complex interplay between dermatological, neurological, immunological, and microbiome-related factors. The multifaceted nature of seborrheic dermatitis underscores the need for a comprehensive approach to its diagnosis, considering age, skin colour, cultural practices, and comorbidities. This is the second in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.

18 April 2025 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
DSDarshana Seeburruth
Darshana Seeburruth
SDSerena Dienes
Serena Dienes
YPYe-Jean Park
Ye-Jean Park
MSMuskaan Sachdeva
Muskaan Sachdeva
SJShubhreet Johal
Shubhreet Johal
SHSameh Hanna
Sameh Hanna